Search clinical trials for: Chidamide; Decitabine; Camrelizumab

Total 3600 results

Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Chinese PLA General Hospital

Recruiting

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Non Hodgkin Lymphoma

China
Chinese PLA General Hospital

Unknown

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

China
Huiqiang Huang

Unknown

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Lymphoma, Extranodal NK-T-Cell | EBV
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Experimental
Chinese PLA General Hospital

Recruiting

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Sun Yat-sen University

Recruiting

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Triple Negative Breast Cancer

China
Sun Yat-sen University

Unknown

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Experimental Tumor

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Zhejiang University

Recruiting

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

T Lymphoblastic Leukemia/Lymphoma

China
Sichuan University

Recruiting

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Leukemia, Myeloid, Acute

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Liling Zhang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Newly Diagnosed Peripheral T-cell Lymphoma

China
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Dong mei

Unknown

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Adenocystic Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

PTCL

China
Ruijin Hospital

Unknown

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Esophageal Cancer

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Peking Union Medical College Hospital
Peking University Third Hospital; Dongzhimen Hospital, Beijing; Beijing Longfu...

Recruiting

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma

China
Sun Yat-sen University

Recruiting

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

China
Guangdong Provincial People's Hospital

Unknown

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Sun Yat-sen University

Recruiting

Chidamide Combined With Toripalimab in Sarcoma

Sarcoma

China
Shandong University

Unknown

A Clinical Trial of the Low Dose Chidamide in the Management of Refractory ITP

Thrombocytopenia

China
Chipscreen Biosciences, Ltd.

Recruiting

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer Stage IV

China
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma

Taiwan
HUYABIO International, LLC.

Completed

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
Peking University

Not yet recruiting

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Esophageal Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (ESCC)

Esophageal Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Oligometastasis | Radiotherapy

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Acute Myeloid Leukemia (Relapsed/Refractory)

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Melanoma

China
Ascentage Pharma Group Inc.

Recruiting

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

NHL, Adult

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
Fujian Medical University Union Hospital

Recruiting

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Radiotherapy | Immunotherapy | Esophageal Neoplasm

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

HNSCC

China

3

Subscribe